Clinical-stage biopharmaceutical company Viking Therapeutics Inc (NASDAQ:VKTX) saw its shares rocket as broker H.C. Wainwright, which initiated coverage on the firm with a “Buy” recommendation. The brokerage firm has set the target price of US$6 it reported in a research report released on Thursday, sending shares more than 63% higher to US$2.33.
centsucher
: New Data from Phase 2 Study of VK2809
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress? 2019
Sichern Sie sich jetzt 50 ? Trade?guthaben1 und handeln Sie Ihre Wert?papiere k?nftig bei der ?g?nstigsten Bank f?r alle Depotmodelle? (Finanztest, Ausgabe 11/2019)!